{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"100","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"4.3","upperLimit":"77.7","value":"66.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"The primary outcome measure will be feasibility of daily 30-minute cryocompression treatments with a target of 60% compliance. Compliance will be measured with patient diaries. Only periods for which diaries exist will be evaluated. Compliance is defined as completion of 60% of prescribed treatment days. Completion of at least 25 of 30 minutes on each day will be considered completion of therapy on the prescribed day.\n\nAnalyses will be primarily descriptive to estimate variances and effect sizes for future work. The proportion of compliance and its 95% confidence interval will be calculated for each cohort.","dispersionType":"95% Confidence Interval","groups":[{"description":"VascuTherm5 vascular compression device Cohort 1 - Grade 2-3 neuropathy - Patients with established neuropathy (e.g. previously received bortezomib-based chemotherapy and have clinically documented CTCAE grade 2 or 3 neuropathies. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.\n\nVascuTherm5 vascular compression device: VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device","id":"OG000","title":"Grade 2-3 Established Neuropathy"},{"description":"VascuTherm5 vascular compression device Cohort 2 Grade 1-2 Neuropathy - Patients with new-onset neuropathy (e.g. currently receiving bortezomib-based chemotherapy have clinically documented CTCAE grade 1 or grade 2 neuropathy to explore its role in preventing worsening of CIPN in patients receiving neurotoxic chemotherapy. Patients undergo home cryocompression therapy treatments using VascuTherm device on their non-dominant hand and foot over 30 minutes daily for 8 weeks.\n\nVascuTherm5 vascular compression device: VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device","id":"OG001","title":"Grade 1-2 New-onset Neuropathy"}],"paramType":"NUMBER","populationDescription":"Not all treated patients returned a diary leading to missing data.","reportingStatus":"POSTED","timeFrame":"Baseline up to 8 weeks of cryocompression therapy","title":"Feasibility - Ability to Complete Daily 30-minute Cryocompression Treatments","type":"PRIMARY","unitOfMeasure":"percentage of compliant participants"}